Drugs / Lecozotan
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT00563732 | Dec 2007 → Sep 2008 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00538889 | Aug → Nov 2007 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00499642 | Jun → Aug 2007 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00494962 | Jun 2007 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00366483 | May 2006 → ? | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00151398 | Oct 2005 → Mar 2008 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00151333 | Feb → Apr 2005 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00277810 | Mar 2006 → Jun 2008 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lecozotan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00151398 ↗ |
| Known as | Lecozotan hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL372205 ↗ |
| Known as | LECOZOTAN HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL372205 ↗ |
| Known as | lecozotan SR | “Drug: lecozotan SR” NCT00151398 ↗ |
| Known as | SRA-333 | “A 3-Month, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Safety, Tolerability, and Efficacy Study Of 3 Doses Of Lecozotan (SRA-333) SR In Outpatients With Mild To...” NCT00151398 ↗ |
| Action | Inhibit | “Serotonin 1a (5-HT1a) receptor antagonist” CHEMBL372205 ↗ |
| Modality | Small molecule | — CHEMBL372205 ↗ |
| Route | Oral | “Administered Orally” NCT00366483 ↗ |
| Target | HTR1A | “Serotonin 1a (5-HT1a) receptor antagonist” CHEMBL372205 ↗ |